By surpassing the 50% inheritance limit of Mendel's law of independent assortment, CRISPR-based gene drives have the potential to fight vector-borne diseases or suppress crop pests. However, contemporary gene drives could spread unchecked, posing safety concerns that limit their use in both laboratory and field settings. Current technologies also lack chemical control strategies, which could be applied in the field for dose, spatial and temporal control of gene drives. We describe in Drosophila the first gene-drive system controlled by an engineered Cas9 and a synthetic, orally-available small molecule.
MAIN TEXT
The Mendelian rules of random assortment dictate that a given gene has a 50% chance of being transmitted to progeny through sexual reproduction (Fig. 1A, top) , though CRISPR-based gene drives breach this barrier by increasing the inheritance limit towards 100% (i.e., super-Mendelian inheritance). This rate allows rapid gene transmission and is ushering in an era of active genetics [1] [2] [3] (Fig. 1A, bottom) , making gene drives potentially applicable in everything from basic research 4 to ecological engineering 4, 5 , including for managing both insect-borne diseases 6, 7 and invasive pest species 5 as well as in ecosystem restoration 4, 5 . For example, gene drives have allowed ~100% transmission of antimalarial 6 or infertility 7 genes within Anopheles mosquito populations in the laboratory, enabling efficient population modification or suppression, respectively. However, multiple concerns and challenges surround the use of gene drives in both laboratory and ecological settings 8 .
The unknown consequences of organisms containing engineered gene drives escaping from either the laboratory or their intended ecological residence have prompted intense interest in strategies for spatially containing these organisms 8 . Furthermore, there are no currently existing methods to precisely control the timing of gene-drive activation, to prevent drives occurring in escaped organisms, and to fine-tune the inheritance probability to a value between 50% and 100%. Such fine-tuning of the inheritance probability would allow for both spatial control of the gene drive in the field as well as fundamental studies on the strengths and limitations of gene drives in laboratory settings. For example, an experimental system could be designed to assess the outcomes of gene drives working at different efficiencies in contained cage trials through the use of fine-tuning, and subsequent computational modeling could identify the key optimization parameters.
CRISPR-based gene drives can achieve super-Mendelian inheritance through a Cas9-induced doublestrand break on the wildtype allele that is repaired by copying from the intact gene-drive allele via homologydirected repair (HDR), replacing a wildtype allele with the engineered gene ( Fig. 1B) [1] [2] [3] . Therefore, controlling the activity of the initial Cas9-induced DNA break could start or stop the drive process at will. We hypothesized that a gene drive employing a synthetic small molecule that could control Cas9 activity would afford precision control of gene drives for multiple reasons. First, small molecules can provide dosage control of Cas9 activity, and their use in regulating a gene drive would convert the output from singular (i.e., fully-on) to analog, wherein the inheritance probability in the population could be fine-tuned to any value between the off-state (50% inheritance) and the fully-on state (~100% inheritance). Second, the effect of small molecules on the on/off state of Cas9 would be rapid, allowing for precise temporal control of the gene drive by controlling the time the small molecule is made available to the organism. For gene drives meant to propagate lethal or sterile traits to the progeny, temporarily switching off Cas9 could be useful for animal husbandry and population expansion during large-scale studies. Restricting Cas9 activity to a narrow temporal window is also important for proper functioning of the gene drive, as persistent Cas9 activity during development gives rise to drive-resistance alleles or mosaic phenotypes formed by non-homologous end-joining (NHEJ) DNA repair processes 6, [9] [10] [11] . Third, by requiring genedrive inheritance to be contingent on the presence of a synthetic small molecule (as opposed to a naturally occurring small molecule), gene drives can be more easily contained. Finally, small molecule-based methods are already widely used to control mosquito populations in the developing world, in part because of their high efficacy and low production and administration costs. Since mosquitoes regularly frequent human habitats, many insecticides (e.g., pyrethroids) are administered as mosquito net coatings or as aerosols in homes instead of the mosquito's natural habitat 12 . Thus, small-molecule control methods for gene drives have a strong foundational basis in field settings.
We envisioned to build a small-molecule system for controlling gene drives with the following attributes.
First, since gene drives are being implemented on various organisms from insects to mammals 13 , the controller should be adaptable to a wide-range of body temperatures (e.g., from 25°C in insects to 37°C in mammals) and cellular physiologies. Second, the small molecule should be synthetic and not naturally occurring for efficient containment. Third, turning one of the gene-drive components (e.g., Cas9) into a controller itself does not additionally complicate the gene-drive circuitry, potentially lowering chances of failure in field applications.
Furthermore, this strategy avoids the use of transcription-based controllers that rely on complex regulation by additional genetic components (e.g. UAS/Gal4 or TetON system). We previously described in mammalian cells a small-molecule-controlled SpCas9 system built by fusing the structurally unstable E. coli dihydrofolate reductase (DHFR) protein to SpCas9 (DHFR-SpCas9-DHFR, or DD-SpCas9) 14 . Upon expression, the DD-SpCas9 fusion protein is targeted for proteasomal degradation unless the DHFR-binding small molecule, trimethoprim (TMP), is added. Because destabilized domains are efficacious in multiple organisms [15] [16] [17] [18] , regulated by a synthetic molecule, provide superior control of DNA-binding proteins over transcription-based controllers 19 , and can control SpCas9 in mammalian cells 14 , we reasoned that this system would provide an ideal gene-drive controller. Furthermore, as the small molecule is required to stabilize DD-SpCas9 in this default-off system, there is reversible dosage control of SpCas9 nuclease activity and an added level of safety in case of escaped organisms ( Fig. 1B) .
We developed a DD-SpCas9 system for Drosophila by testing previously-validated clones of DHFR for those that work at lower temperatures 15 and optimizing them to our system, testing the effective in vivo dose ranges of TMP upon ingestion. We explored several reported clones of DHFR and generated transgenic flies with nos-DD-SpCas9 constructs containing 2-3 DHFR domains at varied positions: N-terminal, C-terminal, and an internal loop previously described to tolerate a small protein-domain insertion 20 (DD1-SpCas9 through DD4-SpCas9, Supplementary Fig. S1 ). We calibrated TMP-dependent SpCas9 activation by targeting an easily identifiable dark body phenotype that is produced upon mutation of the recessive ebony gene. In these optimization experiments, female flies bearing DD-SpCas9 (DD1-DD4) were crossed to males bearing a gRNA targeting ebony under the control of the ubiquitous U6 promoter (Fig. 1C) . Subsequently, female progeny carrying both DD-SpCas9 and U6-gRNA transgenes were fed different doses of TMP and crossed to ebony-/ebony-males (Fig. 1C) . The resulting F2 progeny were scored using the visual phenotyping assay for SpCas9mediated editing of the ebony gene ( Fig. 1D) . While we observed little to no SpCas9 activity with DHFR fusions for DD1-, DD3-, and DD4-SpCas9 based on ebony mutation rates ( Supplementary Fig. S2 ), we observed a greater TMP activation for DD2-SpCas9, which increases gradually over the first four days and then plateaus at the level of constitutively expressed wildtype SpCas9 by days 6-10 at all TMP concentrations tested ( Fig. 1E,   Supplementary Fig. S2 ).
We next sought to establish precision control of gene drives using TMP and a modified gRNA-only drive construct called a CopyCat 21 element that behaves similarly to a gene-drive construct in the presence of a transgenic source of SpCas9, which is itself transmitted in a Mendelian fashion 21, 18 . Briefly, a CopyCat element is composed of a gRNA-expressing gene inserted at the location where such gRNA targets the genome for cleavage; when combined with a transgenic source of Cas9, a Copycat element is capable of copying itself onto the opposing chromosome via HDR. CopyCat elements are unable to spread exponentially in a population and increase only additively each generation based on the initial allele frequency of the Cas9 transgene 8 . The small-molecule-controlled Drosophila system developed herein consisted of two components: 1) a transgenic source of DsRed-marked SpCas9 (or DD2-SpCas9) driven by the vasa germline promoter, which was inserted into the yellow gene coding sequence; and 2) the GFP-marked CopyCat element containing a gRNA under the control of the Drosophila U6:3 promoter ( Fig. 2A) . We tested the gene-drive-based inheritance bias of our system by inserting a GFP-marked CopyCat element at the ebony and white genes (see below), for which homozygous mutants are viable and fertile (Fig. 1D) . This allowed us to measure inheritance rates by following the fluorescent marker and to evaluate failure events (indels) by scoring the visible phenotype (dark body or white eyes without the GFP marker). First, we crossed males carrying the SpCas9 (or DD2-SpCas9) cassette to females containing the ebony CopyCat element (F0; Fig. 2B ). We collected virgin F1 females carrying both the SpCas9 (or DD2-SpCas9) and ebony gRNA, which were crossed to wildtype males (Oregon-R) for F1 germline transmission assessment using a phenotypic analysis of GFP (CopyCat transgene) in the resulting F2 progeny ( Fig. 2B;   Supplementary Fig. S3 ). This experimental design allowed us to assay the germline inheritance ratios of each single F1 female. Wildtype SpCas9 showed an ~65% average inheritance for the ebony CopyCat element and, as expected, this super-Mendelian inheritance was independent of the presence of TMP (Fig. 2C) . In contrast, we observed significant TMP dose-dependent super-Mendelian inheritance for the CopyCat element ( Supplementary Table S1 ) when combined with the DD2-SpCas9 construct. In this setup, Mendelian inheritance values of ~50% were seen in the absence of TMP, as expected, and these values reached an average inheritance of ~62% at the maximum TMP concentration (80 μM) ( Fig. 2C) .
To demonstrate that our approach is generalizable to another locus, we generated a second system using a CopyCat construct that targeted the white gene, causing lack of pigmentation in the fly eye when disrupted (Fig. 1D) . We followed a similar experimental approach by crossing males expressing SpCas9 or DD2-SpCas9 to females carrying the white CopyCat ( Fig. 2D; Supplementary Fig. S3 ) and raising the progeny on 0 to 80 μM of TMP. The white gRNA element driven by SpCas9 displayed an ~90% average inheritance in both the presence and absence of TMP, reinforcing the conclusion that presence of TMP does not affect SpCas9 function and suggesting that the components or location of the white CopyCat result in a greater copying efficiency than the ~65% of their ebony counterparts ( Fig. 2E) . As was the case with the ebony construct, DD2-SpCas9 combined with the white CopyCat element had normal Mendelian inheritance rates of ~50% in the absence of TMP ( Fig. 2E) and, in the presence of TMP, displayed increasing super-Mendelian inheritance rates of 67% (10 μM), 69% (20 μM), 76% (40 μM), and 79% (80 μM), as scored by the GFP phenotype in the F2 progeny ( Fig. 2E, and Supplementary Table 1 ). This demonstrates that the TMP small molecule provides the desired fine-tuning of the super-Mendelian inheritance rate, which could be used to control gene drive systems based on Cas9. Interestingly, in the absence of TMP, we observed only minimal cutting that was phenotypically evaluated using F2 males of the DD2-SpCas9 white CopyCat experiment (0 μM vs. 80 μM), which was possible because the white gene targeted for conversion was located on the same chromosome where the Cas9 was inserted (within the yellow gene coding sequence), and the quantification is given in Supplementary Fig. S4 .
Lastly, we assessed the reversibility of our system by scoring the GFP inheritance of our white CopyCat in a four-generation experiment in which generations F1 and F2 were treated with TMP, while generations F3 and F4 were kept on regular food ( Fig. S5, Supplementary Table 2) . Importantly, we observed complete reversibility of our system over subsequent generations. While the TMP-treated F0-F1 displays super-Mendelian inheritance in the F2 progeny, removal of TMP leads to the F4 progeny showing ~50% inheritance of the white CopyCat element ( Fig. S5, Supplementary Table 2 ). To the best of our knowledge, these findings are the first example of gene drives with an analog output wherein the super-Mendelian inheritance can be controlled by the presence of a small molecule.
We herein report the first example of gene-drive elements controlled by a synthetic, orally available small molecule that can regulate the inheritance probability of the genetic element. The controller is transportable to other systems and compatible with current gene drive configurations. The controller activates a gene drive by requiring a deliberate application of a synthetic molecule, providing a new method for increasing the safety of laboratory experimentation 8 and can be implemented in combination with existing strategies (physical, genetic, ecological) 8 to provide an additional layer of safety for gene-drive containment. For future field applications, a small-molecule-regulated gene drive could be used to control the spread of gene-drive elements in a circumscribed locale or by vaporizing the drug inside homes as done for mosquito-repellent small molecules. Figure 2 , we used the GFP marker as an indicator of successful conversion. We also tracked the scored mosaic phenotype in the eyes (see Supplementary Table S1 ). All genedrive experiments were carried out in a BSL-2 room built for gene-drive purposes at the Biological Sciences Department, University of California San Diego. drive experiments, all constructs were injected into an isogenized Oregon-R (OrR) strain from our laboratory to keep a homogeneous background in all our experiments. All the Cas9 lines were inserted at the same location (yellow gene) to ensure comparable Cas9 expression levels. The CopyCat elements flanked by specific homology arms and marked with GFP were inserted in ebony and white genes. After construct injection, we received the G0 flies in the larval state (80-120 larvae). Once they eclosed, we distributed all G0 adults in different tubes (5-6 females crossed to 5-6 males). Then, G1 progeny were screened for the presence of the specific fluorescent marker in their eyes, which was indicative of marker insertion. Flies positive for the marker
